Natera

Directions Website Contact the practice

Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health.

Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California.

After decades working in oncology, Shelly Glenn became a patient herself. In her story with Patient Worthy, she shares h...
11/10/2026

After decades working in oncology, Shelly Glenn became a patient herself. In her story with Patient Worthy, she shares how she uses Signatera™ every three months to monitor her health in survivorship, and why advocating for yourself matters.

💙Thank you, Shelly, for sharing your voice and for inspiring others.

Read her story:

Becoming the Patient: How Lung Cancer Changed My Life, My Purpose, and My Voice Post author:Patient Worthy Contributor Post published:October 11, 2026 Post category:Lung Cancer Editor’s Note: Patient Worthy is honored to share this patient story, submitted to us by Shelly Glenn. For most of my car...

Natera team members recently attended the ASRM 2026 Scientific Congress & Expo in Baltimore, and the AASLD 2026 Liver Me...
11/09/2026

Natera team members recently attended the ASRM 2026 Scientific Congress & Expo in Baltimore, and the AASLD 2026 Liver Meeting in Denver.

Thank you to the clinicians, colleagues, and partners who stopped by our booths, saw our presentations, and engaged in conversations about how our cell-free DNA tests can help inform more personalized health care decisions.

Medicare coverage for Signatera™ just expanded to the most common type of liver cancer. Signatera has met coverage requi...
11/03/2026

Medicare coverage for Signatera™ just expanded to the most common type of liver cancer.

Signatera has met coverage requirements from the CMS MolDX program in hepatocellular carcinoma (HCC). The coverage includes serial testing in the surveillance setting for patients with early-stage HCC who have no post-surgical evidence of disease.

We’re pleased to share this news as clinical evidence continues to grow.

Read the full press release:
https://ow.ly/Z4mR5103lIZ

We have an exciting milestone to share: Natera’s multi-cancer early detection (MCED) assay recently received a Breakthro...
10/28/2026

We have an exciting milestone to share: Natera’s multi-cancer early detection (MCED) assay recently received a Breakthrough Device designation from the FDA. The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.

Natera’s MCED assay analyzes cell-free DNA in the blood to screen for multiple types of cancer. Devices must meet rigorous criteria to earn this designation.

We look forward to working with the FDA as we aim to detect cancer earlier, and want to congratulate everyone at Natera who has worked hard to support this important program.

https://ow.ly/jbhA5101LPu

10/27/2026

Dr. Shahin Ghadir explains the steps someone can take to gain more answers after experiencing pregnancy loss.

Shahin Ghadir, MD, FACOG HRC Fertility Orange County

Thank you to everyone who stopped by our booth, met our team, and attended our presentations during this year’s American...
10/26/2026

Thank you to everyone who stopped by our booth, met our team, and attended our presentations during this year’s American Society of Nephrology Kidney Week. We, along with our collaborators, presented 18 abstracts, including three oral presentations, featuring real-world analyses from a large database of patients with indicators of kidney disease. Together, the data underscored how genetic testing can support better care in chronic kidney disease (CKD) and added to the growing evidence behind Renasight™, our genetic test for CKD.

https://ow.ly/tg2H51017lf

10/20/2026

In observance of Pregnancy and Infant Loss Awareness Month, Dr. Shahin Ghadir, Reproductive Endocrinology & Infertility Specialist, shares what patients should know after experiencing pregnancy loss.

Shahin Ghadir, MD, FACOG

At this year’s European Society for Medical Oncology (ESMO) Annual Congress, we’re sharing exciting progress in precisio...
10/19/2026

At this year’s European Society for Medical Oncology (ESMO) Annual Congress, we’re sharing exciting progress in precision oncology. Twenty abstracts, including four rapid oral presentations, feature Natera technology across multiple tumor types and treatment modalities.

Learn more about our expanding diagnostics portfolio on our website and connect with us at booth 1015 during the meeting.

https://ow.ly/xoOl50ZZ7Wx

Natera and collaborators are presenting 20 abstracts and showcasing an expanded precision diagnostics portfolio, redefining how cancer is tracked at the molecular level.

We’re honored to share that our Signatera™ test has been named to TIME's Best Inventions of 2026 list. The annual list f...
10/15/2026

We’re honored to share that our Signatera™ test has been named to TIME's Best Inventions of 2026 list. The annual list features life-changing innovations evaluated on originality, efficacy, ambition, and impact.

Signatera is a personalized, molecular residual disease (MRD) test for patients diagnosed with cancer. Built from the unique genomic signature of each patient’s tumor, Signatera detects and quantifies tiny fragments of circulating tumor DNA (ctDNA) in the blood, providing ongoing monitoring for disease recurrence and response to treatment across cancer types. The test also plays an important role in oncology drug development, helping pharmaceutical companies identify patients for clinical trials and accelerate the approval of novel therapies.

Read more: https://ow.ly/aVp750ZY1B7

Find out why Natera Signatera is on TIME's list of 2026's best inventions.

Chance Osborne, marketing manager on our oncology patient engagement team and triple negative breast cancer survivor, re...
10/13/2026

Chance Osborne, marketing manager on our oncology patient engagement team and triple negative breast cancer survivor, recently shared her story with USA TODAY, including how she uses Signatera™ every three months to monitor her health in survivorship.

Thank you, Chance, for your openness and for inspiring others this Breast Cancer Awareness Month. 💗

https://ow.ly/unMz50ZWYWy

Address

Belmont, CA

Alerts

Be the first to know and let us send you an email when Natera posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Natera:

Shortcuts

Share

Category

Nearby clinics